Zydus Lifesciences Ltd.

Cadila Healthcare has informed that it enclosed a copy of press release dated December 13, 2021 titled ‘Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia’.

The above information is a part of company’s filings submitted to BSE.